Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a New Drug Application (NDA) for the treatment of ocular pain following ophthalmic surgery for its lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4mg, for intracanalicular use, which has completed Phase 3 clinical development for post-surgical ocular inflammation and pain. Subject to the approval of the NDA for post-surgical ocular pain, Ocular Therapeutix intends to submit a supplemental NDA for DEXTENZA to broaden its label to include an indication for post-surgical inflammation. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. The company’s first commercial product, the ReSure® Sealant, is the first and only sealant that has been approved by the Food and Drug Administration (FDA) for ophthalmic use.
Aspiring to be a leader in ophthalmology by leveraging its proven hydrogel platform technology to innovate elegant drug product solutions that improve outcomes in ocular diseases and enhance patient and provider experience.